{"id":457785,"date":"2021-03-15T10:37:40","date_gmt":"2021-03-15T14:37:40","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457785"},"modified":"2021-03-15T10:37:40","modified_gmt":"2021-03-15T14:37:40","slug":"apabetalone-treatment-prevents-covid-19-infection-of-human-lung-cells","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apabetalone-treatment-prevents-covid-19-infection-of-human-lung-cells\/","title":{"rendered":"Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells"},"content":{"rendered":"

\nApabetalone Inhibits SARS-CoV-2 Infection at Levels Comparable to Approved Antiviral
\n<\/h2>\n
\n

CALGARY, Alberta, March 15, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) announced today the publishing of a new article titled: \u201cBromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro\u201d, <\/em>on the pre-print server, bioRxiv. The findings, made in collaboration with Dr. Dalia ElGamal\u2019s research group at the University of Nebraska Medical Center (UNMC), Omaha, NE, provide a strong rationale for use of apabetalone, a bromodomain and extraterminal (BET) protein inhibitor, as a therapeutic for COVID-19.<\/p>\n

The publication can be viewed using the following LINK<\/a>.<\/p>\n

\u201cOur COVID-19 research program has yielded some truly extraordinary results, demonstrating apabetalone\u2019s ability to prevent SARS-CoV-2 infection of human lung cells,\u201d said Dr. Ewelina Kulikowski, Senior Vice President, Research & Development at Resverlogix. \u201cReducing cellular entry of virus particles into the lung tissue is one pillar of apabetalone\u2019s unique dual-mechanism \u2013 alongside inhibiting damaging inflammation<\/a> \u2013 in combatting COVID-19.\u201d<\/p>\n

\u201cThis work would not have been possible without the invaluable contribution of Dr. ElGamal and colleagues at UNMC,\u201d said Donald McCaffrey, President and CEO of Resverlogix. \u201cWe are grateful to work with world-class scientific leaders to characterize apabetalone as a therapeutic for COVID-19 infection for the future benefit of patients.\u201d<\/p>\n

\u201cTogether with St. Patrick Reid, a prominent virologist at UNMC who’s lab is dedicated to molecular pathogenesis of emerging viral pathogens, we found that apabetalone clearly inhibited SARS-CoV-2 infection of human lung epithelial cells,\u201d said Dr. Dalia ElGamal, co-author and Assistant Professor at the Eppley Institute for Research in Cancer and Allied Diseases at UNMC. \u201cGiven apabetalone\u2019s anti-inflammatory properties, and its favorable safety profile in human trails, I am excited to see apabetalone move forward in clinical trials for COVID-19.\u201d<\/p>\n

\n Publication Highlights include:<\/strong>\n <\/p>\n